PTC Therapeutics, Inc. (PTCT) Stock

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

PTC Therapeutics, Inc. (PTCT) stock trades at $76.68 with a market capitalization of $6.36B. The stock is valued at a price-to-earnings (P/E) ratio of -32.91, price-to-book of -35.13, price-to-sales of 7.70. Over the past 52 weeks the stock has ranged between $43.17 and $90.87, and currently trades 15.6% below its 52-week high.

On profitability, PTC Therapeutics, Inc. generates a return on equity (ROE) of 99.84% — well above the market average, a sign of a high-quality business, return on capital employed of -3.48%, an operating margin of 16.54%, a net profit margin of -22.58%.

Official website: www.ptcbio.com